Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Researchers Challenge USPSTF's Lung Cancer Screening Criteria
2.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
3.
An ultrasound breast patch with conformability might help with early breast cancer detection.
4.
Does diabetes impact the prognosis of people with colorectal cancer?
5.
A new FDA boxed warning; suicides rocking college campuses; more people getting flu shots than COVID vaccines.
1.
Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education
2.
Personalized Cancer Vaccines and Neoantigen mRNA: A New Era in Oncology
3.
Unveiling the Hidden Benefits of Lymphedema Treatment
4.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
5.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Lung Cancer Congress®
3.
Genito-Urinary Oncology Summit 2026
4.
Future NRG Oncology Meeting
5.
ISMB 2026 (Intelligent Systems for Molecular Biology)
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
2.
Current Scenario of Cancer- The Incidence of Cancer in Men
3.
Navigating the Complexities of Ph Negative ALL - Part X
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge